Swiss pharmaceutical company could launch the first EU treatment for rare disease
The European Medicines Agency (EMA) has approved of the drug Revestive for the treatment of SBS in adults.
The Swiss company Nycomed has taken a big step closer to marketing their drug Revestive for the treatment of adult patients with SBS, or short bowel syndrome, in Europe, after the EMA has recommended the approval of the drug to the European Commision, according to Dagens Pharma.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
